Sodium-glucose cotransporter 2 (SGLT-2) inhibitors play a significant role in the comprehensive management of type 2 diabetes mellitus. Consequently, it is necessary to conduct a comprehensive clinical evaluation of SGLT-2 inhibitors to provide references for the formulation of national drug policy, the selection of medical institution catalogue, and clinical rational use under the background of centralized procurement. The study was led by Yantai Yuhuangding Hospital and supported by Shandong Pharmaceutical Association, and 13 tertiary hospitals in Shandong province participated in the study. Using multi-criteria decision analysis, the Delphi method and other methods combined with evidence-based medical evidence, the consensus was ultimately formulated through seminars and expert consultation. This expert consensus established a scientific, standardized, and highly operational indicator system for SGLT-2 inhibitors, and conducted a comprehensive clinical evaluation of 9 SGLT-2 inhibitors from six dimensions: effectiveness, safety, economy, suitability, accessibility, and innovation. The development of this consensus can provide a theoretical basis for the clinical rational use of SGLT-2 inhibitors and the selection of drugs for medical institutions. It can help improve the quality of pharmaceutical services, better serve the national drug policy needs, and effectively promote rational drug use.

1.赵锐, 胡若飞, 石秀园, 等. 我国药品临床综合评价全面质量管理体系的构建[J]. 中国药房, 2022, 33(12): 1409-1414, 1429. [Zhao R, Hu RF, Shi XY, et al. Construction of total quality management system of clinical comprehensive evaluation of drugs in China[J]. China Pharmacy, 2022, 33(12): 1409-1414, 1429.] DOI: 10.6039/j.issn.1001-0408.2022.12.01.

2.国家卫生健康委. 关于开展药品使用监测和临床综合评价工作的通知（国卫药政函[2019] 80号） [EB/OL]. (2019-04-09)[2024-11-12]. http://www.nhc.gov.cn/yaozs/pqt/201904/31149bb1845e4c019a04f30c0d69c2c9.shtml.

3.国家卫生健康委办公厅. 关于规范开展药品临床综合评价工作的通知（国卫办药政发[2021] 16号） [EB/OL]. (2021-07-28)[2024-11-12]. http://www.nhc.gov.cn/yaozs/s2908/202107/532e20800a47415d84adf3797b0f4869.shtml.

4.American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2024[J]. Diabetes Care, 2024, 47(Suppl_1): S158-S178. DOI: 10.2337/dc24-S009.

5.中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. [Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Chinese Journal of Diabetes Mellitus, 2021, 13(4): 315-409.] DOI: 10.3760/cma.j.cn115791-20210221-00095.

6.国家卫生健康委卫生发展研究中心. 国家药物和卫生技术综合评估中心关于发布心血管病、抗肿瘤、儿童药品临床综合评价技术指南的通知[EB/OL]. (2022-06-29) [2024-11-12]. http://www.nhei.cn/nhei/znfb/202206/c01d87a290664b01bf42a9dad769d69f.shtml.

7.中华医学会糖尿病学分会, 国家基本公共卫生服务项目基层糖尿病防治管理办公室. 国家基层糖尿病肾脏病防治技术指南（2023）[J]. 中华内科杂志, 2023, 62(12): 1394-1405. [Chinese Diabetes Society, National Office of Basic Public Health Service Program for Primary Diabetes Care. National technical guidelines for the prevention and treatment of diabetic kidney disease in primary care (2023)[J]. Chinese Journal of Internal Medicine, 2023, 62(12): 1394-1405.] DOI: 10.3760/cma.j.cn112138-20231017-00223.

8.《钠-葡萄糖共转运蛋白2抑制剂联合胰岛素治疗2型糖尿病中国专家共识》编写委员会. 钠-葡萄糖共转运蛋白2抑制剂联合胰岛素治疗2型糖尿病中国专家共识（2023版）[J]. 中华糖尿病杂志, 2024, 16(1): 9-19. [Chinese Expert Consensus on Combination Therapy of Sodium-glucose Cotransporter 2 Inhibitor and Insulin in the Treatment of Type 2 Diabetes Mellitus Writing Group. Chinese expert consensus on combination therapy of sodium-glucose cotransporter 2 inhibitor and insulin in the treatment of type 2 diabetes mellitus (2023 edition)[J]. Chinese Journal of Diabetes Mellitus, 2024, 16(1): 9-19.] DOI: 10.3760/cma.j.cn115791-20240104-00007.

9.中华医学会, 中华医学会临床药学分会, 中华医学会杂志社, 等. 2型糖尿病基层合理用药指南[J]. 中华全科医师杂志, 2021, 20(6): 615-630. [Chinese Medical Association, Chinese Society of Clinical Pharmacy, Chinese Medical Journals Publishing House, et al. Guideline for rational medication of type 2 diabetes in primary care[J]. Chinese Journal of General Practitioners, 2021, 20(6): 615-630.] DOI: 10.3760/cma.j.cn114798-20210318-00257.

10.Mannucci E, Candido R, Monache LD, et al. 2023 update on Italian guidelines for the treatment of type 2 diabetes[J]. Acta Diabetol, 2023, 60(8): 1119-1151. DOI: 10.1007/s00592-023-02107-x.

11.NICE. Type 2 diabetes in adults: quality standard QS209[EB/OL]. (2023-03-02) [2024-05-23]. https://www.nice.org.uk/guidance/qs209.

12.中华医学会糖尿病学分会, 国家基层糖尿病防治管理办公室. 国家基层糖尿病防治管理手册（2022）[J]. 中华内科杂志, 2022, 61(7): 717-748. [Chinese Diabetes Society, National Office for Primary Diabetes Care. National handbook for the prevention and control of diabetes in primary care (2022)[J]. Chinese Journal of Internal Medicine, 2022, 61(7): 717-748.] DOI: 10.3760/cma.j.cn112138-20220509-00350.

13.《缓解2型糖尿病中国专家共识》编写专家委员会. 缓解2型糖尿病中国专家共识[J]. 中国全科医学, 2021, 24(32): 4037-4048. [Committee of Consensus of Chinese Experts on the Remission of Type 2 Diabetes Mellitus. Consensus of Chinese experts on the remission of type 2 diabetes mellitus[J]. Chinese General Practice, 2021, 24(32): 4037-4048.] DOI: 10.12114/j.issn.1007-9572.2021.01.105.

14.中国老年学和老年医学学会. 老年2型糖尿病慢病管理指南[J]. 中西医结合研究, 2023, 15(4): 239-253. DOI: 10.3969/j.issn.1674-4616.2023.04.006.

15.中国研究型医院学会糖尿病学专业委员会, 中华医学会糖尿病学分会, 北京医学会糖尿病学分会. 实体器官移植后糖尿病患者降糖药物应用专家共识（2024版）[J]. 中华内分泌外科杂志, 2024, 18(2): 156-172. [Diabetology Committee of Chinese Research Hospital Association, Chinese Diabetes Society, Diabetes Branch of Beijing Medical Association. Expert consensus on the use of hypoglycemic drugs in post transplantation diabetes mellitus (2024 edition)[J]. Chinese Journal of Endocrine Surgery, 2024, 18(2): 156-172.] DOI: 10.3760/cma.j.cn115791-20240116-00025-1.

16.Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD[J]. Eur Heart J, 2020, 41(2): 255-323. DOI: 10.1093/eurheartj/ehz486.

17.中国老年2型糖尿病防治临床指南编写组, 中国老年医学学会老年内分泌代谢分会, 中国老年保健医学研究会老年内分泌与代谢分会, 等. 中国老年2型糖尿病防治临床指南（2022年版）[J]. 中华内科杂志, 2022, 61(1): 12-50. [Chinese Elderly Type 2 Diabetes Prevention and Treatment of Clinical Guidelines Writing Group, Geriatric Endocrinology and Metabolism Branch of Chinese Geriatric Society, Geriatric Endocrinology and Metabolism Branch of Chinese Geriatric Health Care Society, et al. Clinical guidelines for prevention and treatment of type 2 diabetes mellitus in the elderly in China (2022 edition)[J]. Chinese Journal of Internal Medicine, 2022, 61(1): 12-50.] DOI: 10.3760/cma.j.cn112138-20211027-00751.

18.国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南（2024版）[J]. 中华老年医学杂志, 2024, 43(2): 105-147. [National Center of Gerontology, Chinese Society of Geriatrics, Diabetes Professional Committee of Chinese Aging Well Association. Guideline for the management of diabetes mellitus in the elderly in China(2024 edition)[J]. Chinese Journal of Geriatrics, 2024, 43(2): 105-147.] DOI: 10.3760/cma.j.issn.0254-9026.2024.02.001.

19.中华医学会内分泌学分会, 中国内分泌代谢病专科联盟. 中国糖尿病合并慢性肾脏病临床管理共识[J]. 中华内分泌代谢杂志, 2024, 40(6): 455-461. [Chinese Society of Endocrinology, China Endocrinology and Metabolism Specialist Alliance. Expert consensus on clinical management for chronic kidney disease in diabetes mellitus in China[J]. Chinese Journal of Endocrinology and Metabolism, 2024, 40(6) :455-461.] DOI: 10.3760/cma.j.cn311282-20240509-00187.

20.Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network Meta-analysis[J]. BMJ Open, 2016, 6(2): e009417. DOI: 10.1136/bmjopen-2015-009417.

21.Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network Meta-analysis[J]. Diabetes Obes Metab, 2016, 18(8): 783-794. DOI: 10.1111/dom.12670.

22.Zilli RW, Rached CDA, Silva FPD, et al. Long-term efficacy of gliflozins versus gliptins for type 2 diabetes after metformin failure: a systematic review and network Meta-analysis[J]. Rev Assoc Med Bras (1992), 2020, 66(4): 458-465. DOI: 10.1590/1806-9282.66.4.458.

23.Bhosle D, Indurkar S, Quadri U, et al. A comparative study of efficacy and safety of different sodium glucose co-transporter 2 (SGLT-2) inhibitors in the management of patients with type II diabetes mellitus[J]. J Assoc Physicians India, 2022, 70(6): 11-12. DOI: 10.5005/japi-11001-0001.

24.Blonde L, Patel C, Wu B, et al. Real-world comparative effectiveness of canagliflozin versus empagliflozin and dapagliflozin in patients with type 2 diabetes in the United States[J]. Adv Ther, 2021, 38(1): 594-606. DOI: 10.1007/s12325-020-01549-x.

25.Davies GM, McNeill ANN, Kruger E, et al. Systematic literature review and network Meta-analysis (NMA) of SGLT2i as monotherapy for type 2 diabetes mellitus (T2DM)[J]. Diabetes, 2018, 67(Suppl_1): 1159. DOI: 10.2337/db18-1159-P.

26.McNeill ANN, Davies GM, Kruger E, et al. SGLT2i dual therapy with metformin (Met) for type 2 diabetes mellitus (T2DM)—systematic literature review and network Meta-analysis (NMA)[J]. Diabetes, 2018, 67(Suppl_1): 1160. DOI: 10.2337/db18-1160-P.

27.McNeill ANN, Davies GM, Kruger E, , et al. Type 2 diabetes mellitus (T2DM) patients with inadequate A1c control on metformin (MET)+ DPP-4i—a network Meta-analysis (NMA) of the efficacy and safety of SGLT2i, GLP-1 analogs, and insulin[J]. Diabetes, 2018, 67(Suppl_1): 1161. DOI: 10.2337/db18-1161-P.

28.Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)[J]. Diabetes Obes Metab, 2018, 20(3): 520-529. DOI: 10.1111/dom.13103.

29.冀颖, 于磊. SGLT2抑制剂对肾脏作用机制的研究进展[J]. 临床肾脏病杂志, 2020, 20(4): 326-331. [Ji Y, Yu L. Advances in the mechanism of action of SGLT2 inhibitors on the kidney[J]. Journal of Clinical Nephrology, 2020, 20(4): 326-331.] DOI: 10.3969/j.issn.1671-2390.2020.04.012.

30.王小楠, 刘洪涛, 董占军. 钠-葡萄糖共转运蛋白2抑制剂对心血管和肾脏作用机制研究进展[J]. 药学服务与研究, 2021, 21(5): 370-373. [Wang XN, Liu HT, Dong ZJ. Research progress of the mechanisms of sodium glucose co-transporter 2 inhibitor on the cardiovascular system and kidney[J]. Pharmaceutical Care and Research, 2021, 21(5): 370-373.] DOI: 10.5428/pcar20210511.

31.中国医师协会内分泌代谢科医师分会, 《恒格列净临床应用专家指导意见》编写组. 恒格列净临床应用专家指导意见[J]. 中华糖尿病杂志, 2023, 15(7): 611-615. [Chinese Society of Endocrinology，Committee of Expert Opinion on Henagliflozin Therapies in Patients with Type 2 Diabetes Mellitus. Expert opinion on Henagliflozin therapies in patients with type 2 diabetes mellitus[J]. Chinese Journal of Diabetes Mellitus, 2023, 15(7): 611-615.] DOI: 10.3760/cma.j.cn115791-20230531-00229.

32.National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0[S/OL]. (2017-11-27)[2024-11-12]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.

33.Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357. DOI: 10.1056/NEJMoa1812389.

34.Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128. DOI: 10.1056/NEJMca1504720.

35.Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes[J]. N Engl J Med, 2020, 383(15): 1425-1435. DOI: 10.1056/NEJMoa2004967.

36.Chen L, Xue Q, Yan C, et al. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network Meta-analysis of randomized clinical trials[J]. Front Endocrinol (Lausanne), 2023, 14: 1256548. DOI: 10.3389/fendo.2023.1256548.

37.Li CX, Liu LY, Zhang CX, et al. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network Meta-analysis of randomized controlled trials[J]. Front Endocrinol (Lausanne), 2023, 14: 1238399. DOI: 10.3389/fendo.2023.1238399.

38.Hu Y, Bai Z. Fournier Gangrene associated with sodium-glucose cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA Adverse Event Reporting System[J]. J Diabetes Res, 2020, 2020: 3695101. DOI: 10.1155/2020/3695101.

39.Tran BA, Updike WH. Sodium-glucose cotransporter 2 inhibitor use associated with Fournier's gangrene: a review of case reports and spontaneous post-marketing cases[J]. Clin Diabetes, 2022, 40(1): 78-86. DOI: 10.2337/cd21-0015.

40.《钠-葡萄糖转运体2抑制剂在慢性肾脏病患者临床应用的中国专家共识（2023年版）》专家组. 钠-葡萄糖转运体2抑制剂在慢性肾脏病患者临床应用的中国专家共识（2023年版）[J]. 中华糖尿病杂志, 2023, 15(12): 1213-1224. [Expert Group of Chinese Expert Consensus on the Clinical Application of Sodium-Glucose Transporter 2 Inhibitors in Patients with Chronic Kidney Disease (2023 edition). Chinese expert consensus on the clinical application of sodium-glucose transporter 2 inhibitors in patients with chronic kidney disease (2023 edition)[J]. Chinese Journal of Diabetes Mellitus, 2023, 15(12): 1213-1224.] DOI: 10.3760/cma.j.cn115791-20231120-00321.

41.中华医学会全科医学分会, 《中国糖尿病肾脏病基层管理指南》编写专家组. 中国糖尿病肾脏病基层管理指南[J]. 中华全科医师杂志, 2023, 22(2): 146-157. [Chinese Society of General Practice, Writing Group of Guideline for Primary Care of Diabetes Kidney Disease in China. Guideline for primary care of diabetes kidney disease in China[J]. Chinese Journal of General Practitioners, 2023, 22(2): 146-157.] DOI: 10.3760/cma.j.cn114798-20221101-01037.

42.国家药品监督管理局. 药物警戒快讯第4期（总第192期）: 英国警示SGLT2抑制剂的生殖器或会阴区坏死性筋膜炎风险[EB/OL]. (2019-04-24) [2024-12-01]. https://www.nmpa.gov.cn/xxgk/yjjsh/ywjjkx/20190424164401150.html.

43.国家药品监督管理局. 药物警戒快讯第8期（总第184期）: 加拿大评估SGLT2抑制剂的胰腺炎风险[EB/OL]. (2018-09-04) [2024-12-01]. https://www.nmpa.gov.cn/xxgk/yjjsh/ywjjkx/20180904112301131.html.

44.国家药品监督管理局. 药物警戒快讯第9期（总第185期）: 美国警告SGLT2降糖药的罕见严重的生殖区感染风险[EB/OL]. (2018-10-19) [2024-12-01]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ywjjkx/20181019171301688.html.

45.国家药品监督管理局. 药物警戒快讯第10期（总第174期）: 加拿大警告坎格列净下肢截肢风险[EB/OL]. (2018-02-07) [2024-12-01]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ywjjkx/20180207144301543.html.

46.国家统计局. 中华人民共和国2023年国民经济和社会发展统计公报[EB/OL]. (2024-02-29) [2024-11-07]. https://www.stats.gov.cn/sj/zxfb/202402/t20240228_1947915.html.

47.Heerspink HJL, Stefánsson BV, CorreaRotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15): 1436-1446. DOI: 10.1056/ NEJMoa2024816.

48.McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36): 35993726. DOI: 10.1093/eurheartj/ehab368.

49.Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 American College of Cardiology/American Heart Association/Heart Failure Society of America guideline for the management of heart failure: executive summary[J]. J Card Fail, 2022, 28(5): 810-830. DOI: 10.1016/j.cardfail.2022.02.009.

50.Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2020, 98(4S): S1-S115. DOI: 10.1016/j.kint.2020.06.019.